Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence Over Tamoxifen and Further Reduction Is Seen When Combined with Exemestane

esmo - Findings from the SOFT and TEXT studies

AI Summary: A new analysis shows adding ovarian function suppression to tamoxifen substantially lowers recurrence in premenopausal breast cancer patients compared with tamoxifen alone, with even greater reduction when switched to exemestane. Clinicians should note the clear endocrine benefit — and patients can sigh with cautious optimism while weighing menopausal side effects.